Anti-obesity Drugs Market 2017–2023
- November, 2017
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
Globally, obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, who were 18 years and older were overweight. Of these over 650 million were obese. An obese individual is at a higher risk of developing chronic diseases such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.
Anti-obesity drugs help in reducing body mass either by dipping the hunger or increasing the consumption of calories. The increasing prevalence of obesity globally is a major factor driving the market. It is principally because of wrong eating habits and swiftly varying regime of people. The increasing ingestion of unhealthy food along with the lack of exercises is intensifying the incidence rate of obesity globally.
Basic activities like reducing the intake of unhealthy diet and inculcating workout are not highly effective, and the medical devices like intragastric balloon and bariatric surgery are highly expensive and has high complications. This shows that there is a wide gap for the treatment of obesity. This unmet need is driving the market for anti-obesity drugs market.
Ill effects, such as the risk of mental illness, suicidal symptoms, stroke, are natively impacting the anti-obesity drugs market. Many drugs that were approved previously were withdrawn because of their side effects. Due to these factors healthcare specialists have an undesirable insight and do not recommend them to their clients.
The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2017–2023. The market is analyzed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the anti-obesity drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India and China are set to be the most attractive destinations due to the large untapped market.
The top FDA approved anti-obesity drugs are Xenical, Saxenda, Contrave, Belviq, and Qsymia. Xenical was the largest selling drug in the market until 2012, but saw a dip in its revenue over the years. However, recently approved Saxenda by Novo Nordisk is gaining large interest among obese people and is growing at a fast growth rate.
Key Players: F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors.
Novo Nordisk, an innovator of drugs in the obesity market, launched Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first launched for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the latest trend in the market. Therefore, big pharmaceutical companies, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk strategy of using diabetes drugs to treat the obesity related problem. This helps the diabetes market players to enter the obesity market. J&J is intended to enter the market for prescription anti-oobesity drugs without further investing in the development of novel molecules.
The report provides complete details about the usage and adoption rate of anti-obesity drugs during the forecast period and the various regions. With that, the key stakeholders can know about the major trends, drivers, and investments, along with the details of the commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding business in this market.
1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Total Addressable Market
3.3 Segmented Addressable Market
3.4 Related Markets
3.4.1 Diabetes Drugs
3.4.2 Active Pharmaceutical Ingredients
3.4.3 Intragastric Balloon
3.4.4 Oncology (Cancer) Drugs
4 Market Outlook
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 Market Characteristics
5.1 Market Evolution
5.2 Market Dynamics
188.8.131.52 High prevalence of obesity
184.108.40.206 Unhealthy lifestyle
220.127.116.11 Chronic nature of obesity
18.104.22.168 Growing awareness of fitness
22.214.171.124 Large untapped market
126.96.36.199 Side effects related to anti-obesity drugs
188.8.131.52 Availability of alternative treatment options
5.3 DRO – Impact Analysis
5.4 Key Stakeholders
6 Drug Details: Market Size and Analysis
6.3 Phentermine/Topiramate ER
6.5 Naltrexone SR/Bupropion SR
6.6 Liraglutide 3.0 mg
7 Types: Market Size and Analysis
7.2 Prescription Drugs (Rx)
7.3 OTC Drugs
8 Regions: Market Size and Analysis
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
8.5.4 Middle East
9 Competitive Landscape
10 Vendors Profiles
10.1 F. Hoffmann-La Roche Ltd.
10.1.2 Business Units
10.1.3 Geographic Revenue
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 GlaxoSmithKline plc
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Vivus, Inc.
10.3.2 Business Focus
10.3.3 SWOT Analysis
10.3.4 Business Strategies
10.4 Orexigen Therapeutics, Inc.
10.4.2 Business Focus
10.4.3 SWOT Analysis
10.4.4 Business Strategies
10.5 Eisai Co., Ltd.
10.5.2 Geographic Revenue
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
11 Companies to Watch for
11.1 Pfizer, Inc.
11.2 Nova Nordisk A/S
11.3 Boehringer Ingelheim GmbH
11.4 Rhythm Pharmaceuticals, Inc.
11.5 Zafgen, Inc.
11.6 Norgine B.V.
11.7 Merck & Co.
11.8 Takeda Pharmaceutical Co., Ltd.
TABLE 1 ANTI-OBESITY DRUGS MARKET REVENUE BY REGIONS, 2016–2023 ($MILLION) 32
TABLE 2 F. HOFFMANN-LA ROCHE: OFFERINGS 43
TABLE 3 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 43
TABLE 4 GLAXOSMITHKLINE PLC: OFFERINGS 48
TABLE 5 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 48
TABLE 6 VIVUS, INC.: OFFERINGS 54
TABLE 7 VIVUS, INC.: RECENT DEVELOPMENTS 54
TABLE 8 OREXIGEN THERAPEUTICS, INC.: OFFERINGS 57
TABLE 9 OREXIGEN THERAPEUTICS, INC.: RECENT DEVELOPMENTS 57
TABLE 10 EISAI CO., LTD.: OFFERINGS 60
TABLE 11 EISAI CO., LTD.: RECENT DEVELOPMENTS 60
TABLE 12 PFIZER: RECENT DEVELOPMENTS 63
TABLE 13 NOVO NORDISK: OVERVIEW 64
TABLE 14 NOVO NORDISK: RECENT DEVELOPMENTS 65
TABLE 15 BOEHRINGER INGELHEIM GMBH: OVERVIEW 65
TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 66
TABLE 17 RHYTHM PHARMACEUTICALS, INC.: OVERVIEW 66
TABLE 18 RHYTHM PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS 66
TABLE 19 ZAFGEN: OVERVIEW 67
TABLE 20 NORGINE B.V.: OVERVIEW 67
TABLE 21 MERCK & CO.: OVERVIEW 68
TABLE 22 MERCK & CO.: RECENT DEVELOPMENTS 68
TABLE 23 TAKEDA PHARMACEUTICAL CO., LTD.: OVERVIEW 69
TABLE 24 TAKEDA PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS 69
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.